Yinuokai (orelabrutinib)

News alerts, weekly reports and conference planners

Company:

Biogen, InnoCare

Drug class:

BTK inhibitor

Related drugs:

‹

›

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
BTK C481R + BTK L528W	Chronic Lymphocytic Leukemia	BTK C481R + BTK L528W	Chronic Lymphocytic Leukemia	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3
BTK T474I	Chronic Lymphocytic Leukemia	BTK T474I	Chronic Lymphocytic Leukemia	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3
BTK C481R	Chronic Lymphocytic Leukemia	BTK C481R	Chronic Lymphocytic Leukemia	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3	orelabrutinib Resistant: C3 – Early Trials orelabrutinib Resistant : C3
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3
MYD88 mutation + CD79B mutation	Lymphoma	MYD88 mutation + CD79B mutation	Lymphoma	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3
CD79A mutation	Diffuse Large B Cell Lymphoma	CD79A mutation	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
MYC expression + BCL2 expression	Diffuse Large B Cell Lymphoma	MYC expression + BCL2 expression	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3

Yinuokai (orelabrutinib)

Associations
(23)

Associations
(23)

Yinuokai (orelabrutinib)

Associations(23)

Associations(23)

Associations
(23)

Associations
(23)